PHS
FATE icon

PFM Health Sciences’s Fate Therapeutics FATE Stock Holding History

PFM Health Sciences’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-881,002
Closed -$13.7M – 65
2019
Q3 		$13.7M Sell
881,002
-666,728
-43% -$12.8M 0.4% 55
2019
Q2 		$31.4M Buy
1,547,730
+266,194
+21% +$4.8M 0.6% 57
2019
Q1 		$22.5M Sell
1,281,536
-189,464
-13% -$2.99M 0.5% 65
2018
Q4 		$18.9M Sell
1,471,000
-30,258
-2% -$422K 0.5% 58
2018
Q3 		$24.5M Buy
+1,501,258
New +$17.8M 0.36% 83

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

PFM Health Sciences's FATE Position: Q4 2019 in Review

PFM Health Sciences sold out of Fate Therapeutics (FATE) in Q4 2019, closing a stake of 881,002 shares — an estimated $13.7M sold.

PFM Health Sciences first reported a position in FATE in Q3 2018 and held it in 5 quarters. The position peaked at $31.4M in Q2 2019. 147 funds tracked by Wall St. Rank hold FATE as of Q4 2019.

  • PFM Health Sciences reported no remaining Fate Therapeutics position as of Q4 2019 after selling out during the quarter.
  • PFM Health Sciences sold 881,002 Fate Therapeutics shares in Q4 2019, an estimated $13.7M.
  • PFM Health Sciences first reported a position in Fate Therapeutics in Q3 2018 and held it in 5 quarters.
  • PFM Health Sciences's Fate Therapeutics position peaked at $31.4M in Q2 2019.
  • 147 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2019.

Based on PFM Health Sciences's 13F filing for Q4 2019, filed 14 Feb 2020.